All sponsors

Changchun GeneScience Pharmaceutical Co., Ltd.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS20
PHASE 3 / 2-39
RECRUITING8
READOUTS ≤12 MONTHS8
READOUT SLIPPED >6 MO30%

Delay Index: of 10 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Changchun GeneScience Pharmaceutical Co., Ltd. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
PEG-somatropin
NCT02375620
P2Active, not recruitingShort Stature Children Born Small for Gestational Age (SGA)962023-12-12 (+77 mo)
recombinant human follicle-stimulating hormone-CTP Fusion protein injection
NCT06561594
P3Not yet recruitingIdiopathic Hypogonadotropic Hypogonadism602024-11-23
T Leuprolide Injectable Emulsion
NCT06449027
P3Active, not recruitingBreast Cancer Subjects2112025-11
GenSci048
NCT06189495
P2RecruitingSystemic Sclerosis Associated Interstitial Lung Disease; Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD)302026-03-31
Cabergoline tablets
NCT07124221
P3RecruitingHyperprolactinemia3822026-11-21 (+14 mo)
PEG-rhGH Injection
NCT07260500
P2RecruitingShort Stature Children Born Small for Gestational Age (SGA)722026-12-23
Nano-crystalline Megestrol Acetate Oral Suspension
NCT06961201
P3Not yet recruitingExtensive-stage Small Cell Lung Cancer (ES-SCLC); The Pre-cachexia or Cachexia Patients Who Have Not Received Systemic Treatment and Are Not Eligible for Curative Therapy942026-12-31
Nano-crystalline Megestrol Acetate Oral Suspension
NCT07150663
P3RecruitingNon-small Cell Lung Cancer1342027-06-30
Nano-crystalline Megestrol Acetate Oral Suspension
NCT06961188
P3Not yet recruitingMetastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity; Untreated With Systemic Therapy1742027-06-30
Nanocrystalline Megestrol Acetate
NCT07356037
P3Not yet recruitingCachexia; Hepatocellular Carcinoma682027-06-30
Nano-crystalline Megestrol Acetate Oral Suspension
NCT06772428
P3Not yet recruitingHead and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors962027-06-30
GenSci120 150 mg
NCT07423533
P2RecruitingRheumatoid Arthritis4502027-09
GenSci048
NCT07547995
P2RecruitingUveitis742027-12-14
GenSci048
NCT06963177
P2RecruitingEndometriosis-related Pain2002028-05-15
GenSci134 Injection
NCT07450001
P1/2Not yet recruitingPediatric Growth Hormone Deficiency1282028-07-18
GenSci134 Injection
NCT07450053
P1/2Not yet recruitingIdiopathic Short Stature1282028-07-18
PEG-hGH Injection
NCT07841678
P3Not yet recruitingSmall for Gestational Age1052028-09
GenSci136 for injection
NCT07936084
P1/2Not yet recruitingPatients With MG (gMG and oMG)722028-12
PEG-somatropin
NCT03255694
P2Active, not recruitingDwarfism3602030-06 (+90 mo)
GS3-007a dry suspension
NCT07264595
P1/2RecruitingPediatric Growth Hormone Deficiency882030-11